26 May 2022 - Janssen Korea said that the Ministry of Health and Welfare would begin to reimburse Tremfya, its psoriatic arthritis treatment, from this month.

According to the current standard, the health authorities will provide reimbursement to patients with active and progressive cases where the response to one or more tumour necrosis factor-alpha inhibitors or interleukin-17 inhibitor was insufficient or in cases where patients had to stop treatment due to side effects or little efficacy.

Read Korea Biomedical Review article